BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics

• Status: Completed
• Trial end date: 2019-08-01

Summary

The primary objectives of this study are to investigate

• the safety and tolerability of increasing single oral doses of BAY 1830839 versus placebo under fasted conditions

• the pharmacokinetics after single ascending oral doses of BAY 1830839 under fasted conditions

• Phase: Phase 1

Details

• Lead Sponsor: Bayer